Protagonist Therapeutics Inc.
Health Care · Biotechnology
Visa sponsorship
1 ▼ 50%
H-1B filings in 12 months
$168k
Median offered salary
0
Open roles in United States
Who they sponsor
Statisticians
1
In the register as Protagonist Therapeutics, Inc., Newark, CA
Other sponsors in the same field
Kashiv Biosciences 
Rani Therapeutics 
Kaigene 
Daiichi Sankyo
Alert me
US Department of Labor · latest filing Jun 2, 2026 · Visa details by country
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Aisling CapitalVia a fund
RA Capital ManagementVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Citi keeps Buy rating for Protagonist Therapeutics stock
Citi kept its Buy rating and set a USD 182.00 target on October 15, 2026. Protagonist Therapeutics stock reported USD 2.29 diluted earnings per share for April-June 2026.
Read more
Report
Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company
Read more
Report
ICOTYDE named one of TIME Magazine's Best Inventions of 2026
October 15, 2026
Please note: the "Read Article" button directs you to an external website.
Read more
Report
Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis
Abreu MT, et al. New Engl J Med. 2026; Epub ahead of print.
Read more
Report
VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy
Kuykendall AT, et al. J Clin Oncol. 2026;Epub ahead of print.
Read more
Report
Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites
Lebwohl MG, et al. Dermatol Ther (Heidelb). 2026;16(10):5049-5068.
Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Af
Read more
Report
Durability of response to icotrokinra in adults with moderate-to-severe plaque psoriasis
Stein Gold L, et al. Br J Dermatol. 2026;195(4):600.
Durability of response to icotrokinra in adults with moderate-to-severe plaque psoriasis: 1-year results from the phase III, placebo- an
Read more
Report
Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis
Soung J, et al. J Am Acad Dermatol. 2026;95(4):1109-1112.
Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Random
Read more
Report
Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings
Warren RB, et al. J Eur Acad Dermatol Venereol. 2026;40(9):1502-1514.
Read more
Report
Improvements in clinical and patient-reported outcomes and durability of response with the targeted oral peptide icotrokinra in adolescents with moderate-to-severe plaque psoriasis
Soung J, et al. J Am Acad Dermatol. 2026;95(4):1103-1106.
Improvements in clinical and patient-reported outcomes and durability of response with the targeted oral peptide icotro
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Newark
United States
HQ
Bay Area - Newark, California
200-500 est. staff
7707 Gateway Boulevard, Suite 140, Newark, CA 94560-1160